SCHEMBL12501979

SCHEMBL12501979

Cc1cn2c(=O)c(C(=O)O)cc(C3CC3)c2c(C)c1-c1ccc2[nH]ncc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.40
FABP4 P15090 2/20 0.40
FABP3 P05413 1/20 0.40
FABP5 Q01469 1/20 0.40
FASN P49327 1/20 0.38
PIK3CA P42336 1/20 0.37
MTOR P42345 1/20 0.37
ROCK2 O75116 4/20 0.36
PIM1 P11309 4/20 0.36
CDK5 Q00535 3/20 0.36
DYRK1A Q13627 3/20 0.36
AURKB Q96GD4 3/20 0.36
JAK2 O60674 2/20 0.36
DAPK3 O43293 2/20 0.36
PRKCG P05129 2/20 0.36
CDK1 P06493 2/20 0.36
PRKACA P17612 2/20 0.36
CDK2 P24941 2/20 0.36
MAPK1 P28482 2/20 0.36
AKT1 P31749 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12502355 0.92 FABP4 (0.38) MAPK14FABP4FABP3FABP5FASN
Potassium Ion SCHEMBL12502399 0.91 MAPK14 (0.39) MAPK14FABP4FABP3FABP5FASN
SCHEMBL12502407 0.90 MAPK14 (0.41) MAPK14FABP4FABP3FABP5FASN
SCHEMBL1290247 0.85 CYP1A2 (0.43) MAPK14FABP4FABP3FABP5FASN
Potassium Ion SCHEMBL12502242 0.84 CYP1A2 (0.36) MAPK14FABP4FASNPIK3CAMTOR
SCHEMBL12502248 0.81 JAK2 (0.42) MAPK14FASNROCK2JAK2KDR
SCHEMBL15261552 0.81 FABP3 (0.45) MAPK14FABP4FABP3FABP5ROCK2
SCHEMBL12502241 0.79 ALOX5AP (0.36) PIK3CAMTORABL1
SCHEMBL12502302 0.78 FGFR1 (0.39) MAPK14ROCK2FGFR1CYP1A2CYP3A4
SCHEMBL12502230 0.78 MAPK14 (0.39) MAPK14FABP4PIK3CAMTORROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3476844-B1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEV GAITHERSBURG INC (US) 2020-11-11 EP disclosed
EP-3476844-B1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEV GAITHERSBURG INC (US) 2020-11-11 EP disclosed
EP-3476844-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES Emergent Product Development Gaithersburg Inc. (US) 2019-05-01 EP disclosed
EP-3476844-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES Emergent Product Development Gaithersburg Inc. (US) 2019-05-01 EP disclosed
US-20190105367-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2019-04-11 US disclosed
US-20190105367-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2019-04-11 US disclosed
US-10155021-B2 Antimicrobial 4-oxoquinolizines EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2018-12-18 US disclosed
EP-3312176-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES Emergent Product Development Gaithersburg Inc. (US) 2018-04-25 EP disclosed
EP-3312176-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES Emergent Product Development Gaithersburg Inc. (US) 2018-04-25 EP disclosed
US-20170232060-A9 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2017-08-17 US disclosed
US-20170106045-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2017-04-20 US disclosed
US-20170106045-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2017-04-20 US disclosed
US-9403818-B2 Antimicrobial 4-oxoquinolizines EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2016-08-02 US disclosed
US-9403818-B2 Antimicrobial 4-oxoquinolizines EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2016-08-02 US disclosed
US-9403818-B2 Antimicrobial 4-oxoquinolizines EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2016-08-02 US disclosed
EP-2670410-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES Evolva SA (CH) 2013-12-11 EP disclosed
US-20130252882-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EVOLVA SA (CH) 2013-09-26 US disclosed
US-20130252882-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EVOLVA SA (CH) 2013-09-26 US disclosed
US-20130252882-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EVOLVA SA (CH) 2013-09-26 US disclosed
WO-2012104305-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EVOLVA SA (CH) 2012-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190105367-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES CUL4A, DCAF15, CUL4B MAPK14 1718/4885FABP4 4593/4885FABP3 4291/4885
US-10155021-B2 Antimicrobial 4-oxoquinolizines DCAF15, CUL4A, CUL4B MAPK14 1637/4885FABP4 4611/4885FABP3 4263/4885
US-20170106045-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES CUL4A, DCAF15, CUL4B MAPK14 1718/4885FABP4 4593/4885FABP3 4291/4885
US-20170232060-A9 ANTIMICROBIAL 4-OXOQUINOLIZINES CUL4A, DCAF15, CUL4B MAPK14 1718/4885FABP4 4593/4885FABP3 4291/4885
US-20130252882-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES CUL4A, DCAF15, CUL4B MAPK14 1718/4885FABP4 4593/4885FABP3 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.